Journal Article

Treatment of Human Immunodeficiency Virus 1-Infected Infants and Children with the Protease Inhibitor Nelfinavir Mesylate

Paul Krogstad, Andrew Wiznia, Katherine Luzuriaga, Wayne Dankner, Karin Nielsen, Merril Gersten, Brad Kerr, Amy Hendricks, Barbara Boczany, Martin Rosenberg, Denna Jung, Stephen A. Spector and Yvonne Bryson

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 28, issue 5, pages 1109-1118
Published in print May 1999 | ISSN: 1058-4838
Published online May 1999 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/514759
Treatment of Human Immunodeficiency Virus 1-Infected Infants and Children with the Protease Inhibitor Nelfinavir Mesylate

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20–30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log10 copies/mL; suppression of plasma HIV-1 RNA levels to <400 copies/mL was observed in 15. Children who began taking at least one new reverse transcriptase inhibitor near the time when nelfinavir mesylate was started, and those with a ⩾24% proportion of CD4 lymphocytes, had a greater chance of achieving and maintaining a decline in plasma HIV- 1 RNA to <400 copies/mL. Suppression of viremia was achieved in children as young as 3 months of age.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.